Download presentation
Presentation is loading. Please wait.
Published byJoanna Ray Modified over 6 years ago
1
Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery
Himanshu Gupta, B.Pharm, M.Pharm, Mohammed Aqil, M.Pharm, PhD, Roop K. Khar, M.Pharm, PhD, Asgar Ali, M.Pharm, PhD, Aseem Bhatnagar, MBBS, MD, Gaurav Mittal, MSc, PhD Nanomedicine: Nanotechnology, Biology and Medicine Volume 6, Issue 2, Pages (April 2010) DOI: /j.nano Copyright © 2010 Elsevier Inc. Terms and Conditions
2
Figure 1 (A) Graph showing particle size distribution of optimized nanosuspension. (B) Graph showing the zeta potential of optimized nanosuspension. (C) Transmission electron micrograph of optimized nanosuspension. Nanomedicine: Nanotechnology, Biology and Medicine 2010 6, DOI: ( /j.nano ) Copyright © 2010 Elsevier Inc. Terms and Conditions
3
Figure 2 (I) XRD diffractograms: A, sparfloxacin; B, PLGA; C, physical mixture; D, sparfloxacin-PLGA nanoparticle system. (II) DSC thermograms: A, sparfloxacin; B, PLGA; C, physical mixture; D, sparfloxacin-PLGA nanoparticle system. Nanomedicine: Nanotechnology, Biology and Medicine 2010 6, DOI: ( /j.nano ) Copyright © 2010 Elsevier Inc. Terms and Conditions
4
Figure 3 (A) In vitro drug release profile of optimized sparfloxacin nanosuspension and marketed formulation. (B) PCP Disso (version 3) best fitted model for in vitro drug release of sparfloxacin nanosuspension. Nanomedicine: Nanotechnology, Biology and Medicine 2010 6, DOI: ( /j.nano ) Copyright © 2010 Elsevier Inc. Terms and Conditions
5
Figure 4 Transcorneal permeation study for the marketed eye drops and the optimized nanosuspension. Nanomedicine: Nanotechnology, Biology and Medicine 2010 6, DOI: ( /j.nano ) Copyright © 2010 Elsevier Inc. Terms and Conditions
6
Figure 5 Diameter of zone of inhibition for the marketed eye drops and the optimized nanosuspension (n = 3). Nanomedicine: Nanotechnology, Biology and Medicine 2010 6, DOI: ( /j.nano ) Copyright © 2010 Elsevier Inc. Terms and Conditions
7
Figure 6 Gamma scintigraphic static whole-body images after 6 hours of administration: (A) marketed formulation; (B) sparfloxacin-PLGA nanosuspension. Nanomedicine: Nanotechnology, Biology and Medicine 2010 6, DOI: ( /j.nano ) Copyright © 2010 Elsevier Inc. Terms and Conditions
8
Figure 7 Time-activity curves showing precorneal drainage.
Nanomedicine: Nanotechnology, Biology and Medicine 2010 6, DOI: ( /j.nano ) Copyright © 2010 Elsevier Inc. Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.